Low-dose estrogen is as effective as high-dose treatment in rats with postmenopausal hypertension

Journal of Cardiovascular Pharmacology

Volumn 63, Issue 2, 2014, Pages 144-151

  Campos, Cristina ^a   Sartorio, Carmem L ^a   Casali, Karina R ^b   Fernandes, Rafael O ^a   Llesuy, Susana ^c   Da Rosa Araujo, Alex S ^a   Belló Klein, Adriane ^a   Rigatto, Katya Vianna ^d  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b INSTITUTO DE CARDIOLOGIA DO RIO GRANDE DO SUL   (Brazil)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

Author keywords

Blood pressure variability; Estrogen therapy; Hydrogen peroxide; NADPH oxidase; Ovariectomized rats; Thioredoxin

Indexed keywords

ANIMALS; AORTA; ARTERIAL PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FEMALE; HYDROGEN PEROXIDE; HYPERTENSION; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OVARIECTOMY; OXIDATION-REDUCTION; PHOSPHORYLATION; POSTMENOPAUSE; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES;

EID: 84894090166     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000034     Document Type: Article

References (65)

1. Yang XP, Reckelhoff JF. Hormonal replacement therapy and cardiovascular disease. Estrogen, hormonal replacement therapy and cardiovascular disease. Curr Opin Nephrol Hypertens. 2011;20:133-138
2. Stramba-Badiale M, Fox KM, Priori SG, et al. Cardiovascular diseases in women: A statement from the policy conference of the European Society of Cardiology. Eur Heart J. 2006;27:994-1005
3. Muzaffar S, Shukla N, Jeremy JY. Nicotinamide adenine dinucleotide phosphate oxidase: A promiscuous therapeutic target for cardiovascular drugs?. Trends Cardiovasc Med. 2005;15:278-282
4. Bengtsson SH, Gulluyan LM, Dusting GJ, et al. Novel isoforms of NADPH oxidase in vascular physiology and pathophysiology. Clin Exp Pharmacol Physiol. 2003;30:849-854
5. Miller AA, Drummond GR, Sobey CG. Novel isoforms of NADPH-oxidase in cerebral vascular control. Pharmacol Ther. 2006;111:928-948
6. OLone R, Knorr K, Jaffe IZ, et al. Estrogen receptors alpha and beta mediate distinct pathways of vascular gene expression, including genes involved in mitochondrial electron transport and generation of reactive oxygen species. Mol Endocrinol. 2007;21:1281-1296
7. Nordberg J, Arner ES. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med. 2001;31: 1287-1312
8. Ago T, Sadoshima J. Thioredoxin1 as a negative regulator of cardiac hypertrophy. Antioxid Redox Signal. 2007;9:679-687
9. Halliwell B, Gutteridge JM, Cross CE. Free radicals, antioxidants, and human disease: Where are we now?. J Lab Clin Med. 1992;119:598-620
10. Cai H, Li Z, Davis ME, et al. Akt-dependent phosphorylation of serine 1179 and mitogen-Activated protein kinase kinase/extracellular signalregulated kinase 1/2 cooperatively mediate activation of the endothelial nitric-oxide synthase by hydrogen peroxide. Mol Pharmacol. 2003;63: 325-331
11. Sugden PH, Clerk A. Akt like a woman: Gender differences in susceptibility to cardiovascular disease. Circ Res. 2001;88:975-977
12. Tanaka T, Nakamura H, Yodoi J, et al. Redox regulation of the signaling pathways leading to eNOS phosphorylation. Free Radic Biol Med. 2005; 38:1231-1242
13. Florian M, Lu Y, Angle M, et al. Estrogen induced changes in Aktdependent activation of endothelial nitric oxide synthase and vasodilation. Steroids. 2004;69:637-645
14. Haynes MP, Sinha D, Russell KS, et al. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res. 2000;87: 677-682
15. Stauss HM, Persson PB. Role of nitric oxide in buffering short-Term blood pressure fluctuations. News Physiol Sci. 2000;15:229-233
16. Tseng CJ, Liu HY, Lin HC, et al. Cardiovascular effects of nitric oxide in the brain stem nuclei of rats. Hypertension. 1996;27:36-42
17. Hansen TW, Thijs L, Li Y, et al. Prognostic value of reading-To-reading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension. 2010;55:1049-1057
18. Schillaci G, Pucci G, Parati G. Blood pressure variability: An additional target for antihypertensive treatment?. Hypertension. 2011;58:133-135
19. Aono T, Sato T, Nishinaga M, et al. Power spectral analysis of spontaneous blood pressure and heart rate variability in elderly hypertensives. Hypertens Res. 1996;19:9-16
20. Stauss HM, Nafz B, Mrowka R, et al. Blood pressure control in eNOS knock-out mice: Comparison with other species under NO blockade. Acta Physiol Scand. 2000;168:155-160
21. Stauss HM, Godecke A, Mrowka R, et al. Enhanced blood pressure variability in eNOS knockout mice. Hypertension. 1999;33:1359-1363
22. Lima SM, Aldrighi JM, Consolim-Colombo FM, et al. Acute administration of 17beta-estradiol improves endothelium-dependent vasodilation in postmenopausal women. Maturitas. 2005;50:266-274
23. Mercuro G, Podda A, Pitzalis L, et al. Evidence of a role of endogenous estrogen in the modulation of autonomic nervous system. Am J Cardiol. 2000;85:787-789, A9
24. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69-75
25. Barton M, Meyer MR. Postmenopausal hypertension: Mechanisms and therapy. Hypertension. 2009;54:11-18
26. Yildirir A. Postmenopausal hormone replacement therapy and the cardiovascular system [Article in Turkish]. Turk Kardiyol Dern Ars. 2010; 38(suppl 1):32-40
27. Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst. 1998;90:814-823
28. Gairard B, Guldenfels C, Haehnel P, et al. Breast density: A major parameter to follow during hormone replacement therapy [Article in French]. Gynecol Obstet Fertil. 2009;37:657-660
29. Lambrinoudaki I, Brincat M, Erel CT, et al. EMAS position statement: Managing obese postmenopausal women. Maturitas. 2010;66:323-326
30. Barp J, Araujo AS, Fernandes TR, et al. Myocardial antioxidant and oxidative stress changes due to sex hormones. Braz J Med Biol Res. 2002;35:1075-1081
31. Siqueira R, Campos C, Colombo R, et al. Influence of estrogen on pulmonary arterial hypertension: Role of oxidative stress. Cell Biochem Funct. 2011;29:543-548
32. Campbell SE, Febbraio MA. Effect of the ovarian hormones on GLUT4 expression and contraction-stimulated glucose uptake. Am J Physiol Endocrinol Metab. 2002;282:E1139-E1146
33. Malliani A, Pagani M, Lombardi F, et al. Cardiovascular neural regulation explored in the frequency domain. Circulation. 1991;84:482-492
34. Stauss HM. Identification of blood pressure control mechanisms by power spectral analysis. Clin Exp Pharmacol Physiol. 2007;34:362-368
35. Evangelho JS, Casali KR, Campos C, et al. Hypercholesterolemia magnitude increases sympathetic modulation and coagulation in LDLr knockout mice. Auton Neurosci. 2010;159:98-103
36. Liochev SI, Fridovich I. Lucigenin (bis-N-methylacridinium) as a mediator of superoxide anion production. Arch Biochem Biophys. 1997;337: 115-120
37. Pick E, Keisari Y. A simple colorimetric method for the measurement of hydrogen peroxide produced by cells in culture. J Immunol Methods. 1980;38:161-170
38. Akerboom TP, Sies H. Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. Methods Enzymol. 1981;77:373-382
39. Sartorio CL, Fraccarollo D, Galuppo P, et al. Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. Hypertension. 2007;50:919-925
40. Klein D, Kern RM, Sokol RZ. A method for quantification and correction of proteins after transfer to immobilization membranes. Biochem Mol Biol Int. 1995;36:59-66
41. Valdez LB, Zaobornyj T, Boveris A. Functional activity of mitochondrial nitric oxide synthase. Methods Enzymol. 2005;396:444-455
42. Granger DL, Anstey NM, Miller WC, et al. Measuring nitric oxide production in human clinical studies. Methods Enzymol. 1999;301:49-61
43. Paigel AS, Ribeiro RF Jr, Fernandes AA, et al. Myocardial contractility is preserved early but reduced late after ovariectomy in young female rats. Reprod Biol Endocrinol. 2011;9:54
44. Flues K, Paulini J, Brito S, et al. Exercise training associated with estrogen therapy induced cardiovascular benefits after ovarian hormones deprivation. Maturitas. 2010;65:267-271
45. Silva RJ, Bernardes N, Brito Jde O, et al. Simvastatin-induced cardiac autonomic control improvement in fructose-fed female rats. Clinics (Sao Paulo). 2011;66:1793-1796
46. He XR, Wang W, Crofton JT, et al. Effects of 17beta-estradiol on the baroreflex control of sympathetic activity in conscious ovariectomized rats. Am J Physiol. 1999;277:R493-R498
47. Masi CM, Hawkley LC, Berry JD, et al. Estrogen metabolites and systolic blood pressure in a population-based sample of postmenopausal women. J Clin Endocrinol Metab. 2006;91:1015-1020
48. Elias AN, Meshkinpour H, Valenta LJ. Attenuation of hypertension by conjugation estrogens. Nephron. 1982;30:89-92
49. Magness RR, Rosenfeld CR. Local and systemic estradiol-17 beta: Effects on uterine and systemic vasodilation. Am J Physiol. 1989;256: E536-E542
50. Hayashi T, Fukuto JM, Ignarro LJ, et al. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: Implications for atherosclerosis. Proc Natl Acad Sci U S A. 1992;89:11259-11263
51. Wellman GC, Bonev AD, Nelson MT, et al. Gender differences in coronary artery diameter involve estrogen, nitric oxide, and Ca(2+)-dependent K+ channels. Circ Res. 1996;79:1024-1030
52. Czarnecka D, Posnik-Urbanska A, Kawecka-Jaszcz K, et al. Indices of autonomic nervous system activity in women with mild hypertension in the perimenopausal period. Kardiol Pol. 2009;67:243-251
53. Head GA, Obeyesekere VR, Jones ME, et al. Aromatase-deficient (ArKO) mice have reduced blood pressure and baroreflex sensitivity. Endocrinology. 2004;145:4286-4291
54. El-Mas MM, Abdel-Rahman AA. Longitudinal assessment of the effects of oestrogen on blood pressure and cardiovascular autonomic activity in female rats. Clin Exp Pharmacol Physiol. 2009;36:1002-1009
55. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-To-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895-905
56. Wagner AH, Schroeter MR, Hecker M. 17beta-estradiol inhibition of NADPH oxidase expression in human endothelial cells. Faseb J. 2001; 15:2121-2130
57. Gao L, Wang W, Li YL, et al. Sympathoexcitation by central ANG II: Roles for AT1 receptor upregulation and NAD(P)H oxidase in RVLM. Am J Physiol Heart Circ Physiol. 2005;288:H2271-H2279
58. Dantas AP, Tostes RC, Fortes ZB, et al. In vivo evidence for antioxidant potential of estrogen in microvessels of female spontaneously hypertensive rats. Hypertension. 2002;39:405-411
59. Nakamura H, Nakamura K, Yodoi J. Redox regulation of cellular activation. Annu Rev Immunol. 1997;15:351-369
60. Haendeler J, Tischler V, Hoffmann J, et al. Low doses of reactive oxygen species protect endothelial cells from apoptosis by increasing thioredoxin-1 expression. FEBS Lett. 2004;577:427-433
61. Drechsel DA, Patel M. Respiration-dependent H2O2 removal in brain mitochondria via the thioredoxin/peroxiredoxin system. J Biol Chem. 2010;285:27850-27858
62. Simoncini T, Hafezi-Moghadam A, Brazil DP, et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 2000;407:538-541
63. Xue B, Singh M, Guo F, et al. Protective actions of estrogen on angiotensin II-induced hypertension: Role of central nitric oxide. Am J Physiol Heart Circ Physiol. 2009;297:H1638-H1646
64. Wang PH, Horng HC, Cheng MH, et al. Standard and low-dose hormone therapy for postmenopausal women-focus on the breast. Taiwan J Obstet Gynecol. 2007;46:127-134
65. Lundstrom E, Wilczek B, von Palffy Z, et al. Mammographic breast density during hormone replacement therapy: Effects of continuous combination, unopposed transdermal and low-potency estrogen regimens. Climacteric. 2001;4:42-48